TSHA - CIK 0001806310
The table below shows Taysha Gene Therapies, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $276.58M | $297.34M | $312.76M | $116.59M | $157.69M | $172.74M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $282.25M |
| $299.95M |
| $316.26M |
| $120.71M |
| $161.56M |
| $178.47M |
| Property, plant & equipment | $6.45M | $6.80M | $6.96M | $7.24M | $7.61M | $10.51M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $300.35M | $316.55M | $333.33M | $138.36M | $180.22M | $200.39M |
| Accounts payable | $4.56M | $5.44M | $7.71M | $4.33M | $4.93M | $8.72M |
| Total current liabilities | $20.10M | $28.63M | $25.35M | $22.56M | $29.34M | $34.18M |
| Long-term debt | $48.96M | $50.85M | $41.05M | $42.45M | $42.97M | $37.84M |
| Total liabilities | $88.41M | $97.56M | $84.60M | $83.30M | $91.42M | $91.53M |
| Retained earnings | -$753.71M | -$683.45M | -$650.72M | -$623.83M | -$583.52M | -$558.00M |
| Total equity | $211.94M | $218.99M | $248.73M | $55.06M | $88.80M | $108.87M |